Respiratory Tracker: Trial updates and treatment milestones drive UK HCP respiratory conversations

Throughout April-June 2025, CREATION Pinpoint® tracked the conversations of UK online healthcare professionals (HCPs) discussing respiratory diseases on X (Twitter). We analysed 3,194 posts discussing respiratory diseases by 916 HCPs.

This quarter, UK healthcare professionals (HCPs) remained highly active online, engaging in discussions around major developments in respiratory health. The most discussed conditions were lung cancer (760 mentions), asthma (667 mentions), and COPD (301 mentions), each reflecting unique peaks in conversation:

1. Lung cancer dominated with ASCO-driven trial discussions

Lung cancer was once again the most discussed respiratory condition this quarter. However, this time, HCP conversation was largely driven by clinical data shared during the ASCO 2025 annual meeting, held from May 30th to June 3rd. The spike occurred on June 1st, when trial updates in non-small cell lung cancer (NSCLC) were presented. HCPs served as data disseminators during ASCO, an archetype CREATION.co has identified before. 

Examples of trials discussed included:

• KRYSTAL-7 (Mirati Therapeutics): adagrasib + pembrolizumab in KRAS G12C NSCLC
• SOHO-1 (Bayer): sevabertinib in HER2-mutant NSCLC
• HERTHENA-Lung02 (Merck): patritumab deruxtecan in EGFR-mutated NSCLC, which received mixed reactions.

Dr. Tom Newsom-Davis, a thoracic medical oncologist, was the most active contributor during the spike, accounting for 33% of the conversation on June 1st.  As our research has shown, “HCPs are not just passive recipients of congress data- they’re active amplifiers, bringing their own perspectives and interpretations to their online networks.” 

KRYSTAL-7: Ada + Pembro, KRAS G12C NSCLC, Ph2

✅ORR 44% ITT, 61% PD-L1 >50%
✅mPFS 11.0m ITT, 26.7m PD-L1 hi
🔹 By comparison, Pembro 7-8m, chemoIO 9m
✅mOS 18.3m, NR PD-L1 hi

❗️60% Gr3+ TRAE: GI & liver
❗️High dose redn & interr

Active, AEs common, Ph3 ongoing#LCSM #ASCO25 pic.twitter.com/JxWpl0dcJj

— Tom Newsom-Davis (@tnewsomdavis) June 1, 2025

2. Asthma discussion revolved around global awareness days and paediatric insights

Asthma conversations peaked at two distinct points this quarter, each linked to major awareness initiatives.

The first peak was during the Paediatric Respiratory Conference (#paedresp2025), where HCPs highlighted unmet needs in paediatric asthma care, amplifying content that called attention to research, disease burden, and the importance of improved clinical outcomes for children.

https://x.com/KarenLuyt/status/1907753445295067302

The second peak occurred during World Asthma Day, which HCPs used as an opportunity to promote asthma action plans, raise awareness of environmental triggers, and stress the importance of physician-led education.

It’s #WorldAsthmaDay. Asthma isn’t always visible. It’s daily breathlessness, stress, stigma and yes, inequality.
Let’s talk air quality, asthma plans, and nurse led education.
Change starts with awareness.#AsthmaAwareness #TheDiverseNurse pic.twitter.com/8dWN411Qfm

— Dawn Jarvis Ltd: The Diverse Nurse (@DawnDiverse) May 6, 2025

2. A “good day” for COPD patients as approvals drive HCP online discussions

On May 12, COPD mentions surged following news that Trixeo Aerosphere had received approval in the UK. Many HCPs reshared a post from Professor John Hurst, describing it as a “good day for people living with COPD, and the [world].”

World first!@MHRAgovuk approves the first pMDI for #COPD with a new propellant having near-zero global warning potential.

pMDIs are essential medicines.

Kudos to all involved. A good day for people living with COPD, and the 🌎.https://t.co/btNqZtbCoq

— John Hurst (@ProfHurst) May 12, 2025

Moreover, the role of biologic therapies, particularly mepolizumab, was also a focus in HCP discussions. Following its FDA approval for eosinophilic COPD, based on the METREX, METREO, and MATINEE trials, UK HCPs amplified the data from their peers; they also noted more mixed results in acute settings.

Fascinating new study – congratulations Neil Greening and team. Mepolizumab did not provide benefit in COPD patients admitted to hospital with eosinophilic exacerbations. No reduction in future risk of readmission. Trend towards benefit on exacerbationshttps://t.co/mzQprqWlH8

— James D Chalmers (@ProfJDChalmers) May 1, 2025

Beyond individual disease posts, Asthma + Lung UK was frequently mentioned in HCP respiratory discussions as a trusted source. 57 HCPs mentioned the charity in 123 posts.

So proud of the @rehab_pulmonary team for their boundless enthusiasm to promote #pulmonaryrehabweek25 with a cake sale today with @HIOWH_NHSFT to raise awareness for @asthmalunguk #loveyourlungs 🫁🫁🫁 https://t.co/suNqPu288k

— Kelly Wainwright 💙 (@kellywainw) June 18, 2025

Working hard to reduce inequalities and early diagnosis in #respiratory care @asthmalunguk @_SarahSleet pic.twitter.com/d2DuKLQxdL

— Teresa Burgoyne (@golfingal15) May 28, 2025

HCPs called for cleaner air and policy change, emphasised the importance of pulmonary rehab and ventilator support, and supported Asthma + Lung UK’s push for improved training to tackle inequalities in respiratory care. Its focus on digital engagement, through online communities and educational resources, was also well received. 

So lovely to see feedback like this, a skilled and capable workforce is essential for high quality care – this is the reason why we do it! #hcp #Respiratory #education #asthma @ARNS_UK @asthmalunguk @CHAHAsthma https://t.co/PYCxCNvNyZ

— viv marsh (@vivmarsh) June 9, 2025

Many patients with #asthma turn to Online Health Communities. Moderators play a crucial role in guiding and protecting them.

As healthcare expands to digital spaces, more research&support is neededhttps://t.co/8DVgnMC0tq@QMUL_WIPH @asthmalunguk @HealthUnlocked @NIHRresearch

— Anna De Simoni (@Anna_De_Simoni) May 2, 2025

Each month, we track the HCP conversation relating to respiratory disease. You can read other editions in the Respiratory Tracker archive .

You can also keep updated with other pharmaceutical tracking updates, including how HCPs engage with Top 50 pharma and the product approvals that are catching their attention.  To receive updates straight to your inbox you can sign up for our monthly eJournal with our latest HCP insights. 

If you want to dig deeper into what we have seen this month then please get in touch. 

Methodology

• CREATION Pinpoint® was used to analyse 3,194 mentions on X from 916 HCPs in the UK discussing respiratory disease and related terms, throughout April-June 2025.